We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RAPIBLYK (Phebra Pty Ltd)
Product name
RAPIBLYK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
78 (120 working days)
Active ingredients
landiolol hydrochloride
Registration type
NCE/ NBE
Indication
RAPIBLYK is indicated in adults for:
- supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
- non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.